In re Aggrenox Antitrust Litig., MDL No. 02516 (D. Ct.)
A proposed $54 million settlement has been reached in this class action lawsuit regarding the prescription drug Aggrenox® (aspirin/extended-release dipyridamole). The lawsuit claims that Defendants Boehringer Ingelheim and Teva Pharmaceutical hurt competition and violated state laws by delaying the availability of less-expensive generic versions of Aggrenox®. Click here for more information.